Found 22 Lancaster General Health trials
A listing of Lancaster General Health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Sort by:
The purpose of the study is to evaluate the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of HFpEF. This study will evaluate a personalized cardiac pacing rate as a treatment for symptomatic heart failure with preserved ejection fraction (LVEF ≥50%).
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an add-on with statin therapy and on the market to lower LDL-C in high-risk populations.
This is a multicenter, open-label extension of the ION-682884-CS2 Study (CARDIO-TTRansform) and of the ISIS 420915-CS101 Study. Eligible participants will receive eplontersen once every 4 weeks for up to 36 months or 6 months after eplontersen is approved and available in the site's country, whichever occurs first. Participants will also …
The PK Papyrus Covered Coronary Stent System (PK Papyrus) received approval under a Humanitarian Device Exemption (HDE H170004) from the Food and Drug Administration on September 14, 2018 and is only indicated for treatment of acute perforations of native coronary arteries and coronary bypass grafts in vessels 2.5 to 5.0 …
This study aims to test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications. This is for patients with heart failure who are already receiving current …
The purpose of this study is to:Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) eventsEvaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or deathEvaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related …
PURPOSE The AMPLATZER Post-infarct Muscular VSD Occluder device remains a HUD. This study protocol outlines the compassionate clinical use of the AMPLATZER VSD Occluder device for treating muscular Ventricular Septal Defects (VSDs) in patients who are not candidates for traditional surgical repair. VSDs are congenital heart conditions characterized by abnormal …
The overall objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect data from individuals evaluated for or receiving treatment with novel (or new) FDA-approved therapies for Alzheimer's disease (AD). It will follow and record information about people's health, safety, brain scans, and long-term health outcomes during their regular memory care.
This post-market registry serves as an ongoing source of product performance, patient safety, and clinical outcomes for a variety of different products. The research design allows products to be added once they are released on the market. Patients are enrolled and followed according to their care provider’s normal care routine.
Please choose between Voice or SMS based delivery of verification code
or